Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.

Launched by UNIVERSITY HOSPITAL, LIMOGES · Nov 6, 2013

Keywords

ClinConnect Summary

Recent evidence about the pharmacokinetics and pharmacodynamics of aminoglycosides strongly supports administration of aminoglycosides before, rather than after, hemodialysis. Therapeutic drug monitoring using pharmacokinetic modeling is currently used in non-hemodialysis patients. However, the PK tools employed are not suitable to dialysis patients.

For aminoglycosides, the ratio of peak to Minimal Inhibitory Concentration (MIC) has been shown to be the parameter that best correlates with clinical efficacy, whilst prolonged exposure to high concentrations have been related to either nephr...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age upper to 18 years
• • Patients hospitalized in the "Service de Néphrologie - Hémodialyse, Transplantations, CHU de Limoges"
• • Patients requiring chronic hemodialysis
• • Patients requiring a treatment by aminoglycosides
• • Patients willing to give their written informed consent for their participation to the study
• • Patients affiliated to the French social security system or equivalent
• Exclusion Criteria:
• • Patients under legal protection
• • Patients unable or unwilling to provide informed consent and not under legal protection
• • Patients deprived of liberty
• • Contraindications to gentamicin
• • Pregnant or breast-feeding women or women of childbearing potential without efficient contraception (based on declaration)
• • Patients with any altered mental status or any psychiatric condition that would interfere with the understanding of the study
• • Patients enrolled in another clinical trial testing drugs or therapeutic strategies

Trial Officials